Cargando…
Inhibition of PCSK9 enhances the antitumor effect of PD-1 inhibitor in colorectal cancer by promoting the infiltration of CD8(+) T cells and the exclusion of Treg cells
Immunotherapy especially immune checkpoint inhibitors (ICIs) has brought favorable clinical results for numerous cancer patients. However, the efficacy of ICIs in colorectal cancer (CRC) is still unsatisfactory due to the poor median progression-free survival and overall survival. Here, based on the...
Autores principales: | Wang, Rui, Liu, Hongchuan, He, Peng, An, Duopeng, Guo, Xiaohan, Zhang, Xuyao, Feng, Meiqing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393481/ https://www.ncbi.nlm.nih.gov/pubmed/36003387 http://dx.doi.org/10.3389/fimmu.2022.947756 |
Ejemplares similares
-
Potentiating CD8(+) T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling
por: Yuan, Juanjuan, et al.
Publicado: (2021) -
Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells
por: Noyes, David, et al.
Publicado: (2022) -
Correction to: Potentiating CD8(+) T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling
por: Yuan, Juanjuan, et al.
Publicado: (2021) -
Targeting PCSK9 reduces cancer cell stemness and enhances antitumor immunity in head and neck cancer
por: Yang, Qi-Chao, et al.
Publicado: (2023) -
Reversal of Multidrug Resistance by Apolipoprotein A1-Modified Doxorubicin Liposome for Breast Cancer Treatment
por: An, Duopeng, et al.
Publicado: (2021)